Novelion Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch NVLNF and buy or sell other stocks, ETFs, and their options commission-free!

About NVLNF

Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. 

CEO
Ben Harshbarger
CEOBen Harshbarger
Employees
Employees
Headquarters
Vancouver, British Columbia
HeadquartersVancouver, British Columbia
Founded
1981
Founded1981
Employees
Employees

NVLNF Key Statistics

Market cap
13.77M
Market cap13.77M
Price-Earnings ratio
-0.12
Price-Earnings ratio-0.12
Dividend yield
Dividend yield
Average volume
250.82K
Average volume250.82K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$1.60
52 Week high$1.60
52 Week low
$0.54
52 Week low$0.54

Stock Snapshot

Novelion Therapeutics(NVLNF) stock is priced at $0.70, giving the company a market capitalization of 13.77M. It carries a P/E multiple of -0.12.

During the trading day, Novelion Therapeutics(NVLNF) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 250.82K.

The stock's 52-week range extends from a low of $0.54 to a high of $1.60.

The stock's 52-week range extends from a low of $0.54 to a high of $1.60.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.